Dishman Pharmaceuticals and Chemicals has informed that the Board of Directors of the Company at its meeting held on February 24, 2016, has considered and recommended a bonus issue of equity shares in the ratio of 1 equity share for every 1equity share held, as on the record date to be determined by the Board. The Bonus issue of equity shares will be subject to approval by the Shareholders, through postal ballot and the record date will be announced separately. The Bonus issue will be made by way of capitalization of such sum standing to the credit of Securities Premium Account and/or General Reserves of the Company, as may be considered necessary by the Board. The above proposal for issuance of Bonus Shares was not part of the agenda to the Board Meeting held on February 24, 2016 and was decided at the Board Meeting.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: